

Freedom of Information Request: Our Reference CTMUHB_177_22

You asked:

Q1. How many patients has your Health Board treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL) - 19**
- **Mantle Cell Lymphoma (MCL) - 9**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to – n/a**

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) - nil**
- **Calquence (acalabrutinib) - 6**
- **FCR (fludarabine + cyclophosphamide + rituximab) – *Less than 5**
- **Gazyva (obinutuzumab) + chlorambucil - nil**
- **Imbruvica (ibrutinib) - 8**
- **Venclexta (venetoclax) – *Less than 5**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab) - nil**
- **Venclexta (venetoclax) + rituximab - nil**
- **Zydelig (idelalisib) + rituximab - nil**
- **Any other systemic anti-cancer therapy – nil**

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) – *Less than 5**
- **Imbruvica (ibrutinib) – *Less than 5**
- **Imbruvica (ibrutinib) + rituximab – *Less than 5**
- **R-BAC (rituximab, bendamustine and cytarabine) - nil**
- **R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) - nil**
- **Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) - nil**
- **Velcade (bortezomib) + chemotherapy - nil**
- **Any other systemic anti-cancer therapy - nil**
- **Stem cell transplant - nil**
- **Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells – nil**

* Please note exact figures have been withheld due to the low numbers involved. This is due to the potential risk of identification if we released the number of patients for the specific year who have been admitted with this condition, which might then be linked with other information available in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This

exemption is absolute and therefore there is no requirement to apply the public interest test.

Q4. Does your Health Board currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

No

Q5. Does your Health Board currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

No